Biofilm infections, their resilience to therapy and innovative treatment strategies

Journal of Internal Medicine

Volumn 272, Issue 6, 2012, Pages 541-561

  Romling U ^a   Balsalobre, C ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

(p)ppGpp; Biofilm infections; C di AMP; C di GMP; cAMP; Second messenger

Indexed keywords

AJOENE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIOXIDANT; CURLICIDE; CYCLIC AMP; FURANONE DERIVATIVE; GARLIC EXTRACT; GENTAMICIN; MANNITOL; PILICIDE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; ANTIOXIDANT ACTIVITY; BACTERIAL INFECTION; BIOFILM; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ESCHERICHIA COLI; FOREIGN BODY; HEALTH CARE COST; HUMAN; IMMUNE SYSTEM; IMMUNOSTIMULATION; INFECTION; INFECTION RESISTANCE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROCESSES; BIOFILMS; CYCLIC GMP; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; PSEUDOMONAS AERUGINOSA; SECOND MESSENGER SYSTEMS; STAPHYLOCOCCUS; THERAPIES, INVESTIGATIONAL;

EID: 84869758403     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12004     Document Type: Review

References (163)

1. Henrici AT. Studies of freshwater bacteria: I. A direct microscopic technique. J Bacteriol 1933; 25: 277-87.
2. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980; 28: 546-56.
3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
4. Claret L, Miquel S, Vieille N, Ryjenkov DA, Gomelsky M, Darfeuille Michaud A. The flagellar sigma factor FliA regulates adhesion and invasion of Crohn disease-associated Escherichia coli via a cyclic dimeric GMP-dependent pathway. J Biol Chem 2007; 282: 33275-83.
5. Kumagai Y, Matsuo J, Cheng Z, Hayakawa Y, Rikihisa Y. c-di-GMP signaling regulates intracellular aggregation, sessility, and growth of Ehrlichia chaffeensis. Infect Immun 2011; 79: 3905-12.
6. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 2012; 36: 616-48.
7. Lynch AS, Robertson GT. Bacterial and fungal biofilm infections. Annu Rev Med 2008; 59: 415-28.
8. Wolcott RD, Rhoads DD, Bennett ME et al. Chronic wounds and the medical biofilm paradigm. J Wound Care 2010; 19: 45-6, 8-50, 2-3.
9. Wingender J, Flemming HC. Biofilms in drinking water and their role as reservoir for pathogens. Int J Hyg Environ Health 2011; 214: 417-23.
10. Marks LR, Parameswaran GI, Hakansson AP. Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo. Infect Immun 2012; 80: 2744-60.
11. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003; 57: 677-701.
12. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol 2009; 11: 1034-43.
13. Hall-Stoodley L, Stoodley P, Kathju S et al. Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol 2012; 65: 127-45.
14. Montanaro L, Speziale P, Campoccia D et al. Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol 2011; 6: 1329-49.
15. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000; 54: 49-79.
16. Lewis K. Persister cells. Annu Rev Microbiol 2010; 64: 357-72.
17. Daddi Oubekka S, Briandet R, Fontaine-Aupart MP, Steenkeste K. Correlative time-resolved fluorescence microscopy to assess antibiotic diffusion-reaction in biofilms. Antimicrob Agents Chemother 2012; 56: 3349-58.
18. Haagensen JA, Klausen M, Ernst RK et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007; 189: 28-37.
19. Rohde H, Frankenberger S, Zähringer U, Mack D. Structure, function and contribution of polysaccharide intercellular adhesin (PIA) to Staphylococcus epidermidis biofilm formation and pathogenesis of biomaterial-associated infections. Eur J Cell Biol 2010; 89: 103-11.
20. Connolly KL, Roberts AL, Holder RC, Reid SD. Dispersal of Group A streptococcal biofilms by the cysteine protease SpeB leads to increased disease severity in a murine model. PLoS ONE 2011; 6: e18984.
21. Sanchez CJ, Kumar N, Lizcano A et al. Streptococcus pneumoniae in biofilms are unable to cause invasive disease due to altered virulence determinant production. PLoS ONE 2011; 6: e28738.
22. Donlan RM. Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis 2011; 52: 1038-45.
23. Renner LD, Weibel DB. Physicochemical regulation of biofilm formation. MRS Bull 2011; 36: 347-55.
24. Cegelski L, Pinkner JS, Hammer ND et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 2009; 5: 913-9.
25. Yang L, Liu Y, Wu H et al. Combating biofilms. FEMS Immunol Med Microbiol 2011; 65: 146-57.
26. Sharma SK, Dai T, Kharkwal GB et al. Drug discovery of antimicrobial photosensitizers using animal models. Curr Pharm Des 2011; 17: 1303-19.
27. Christensen LD, van Gennip M, Jakobsen TH et al. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother 2012; 67: 1198-206.
28. McDougald D, Rice SA, Barraud N, Steinberg PD, Kjelleberg S. Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal. Nat Rev Microbiol 2012; 10: 39-50.
29. Müsken M, Di Fiore S, Römling U, Häussler S. A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc 2010; 5: 1460-9.
30. Römling U, Gomelsky M. Galperin, M.Y. c-di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 2005; 57: 629-39.
31. Itoh Y, Wang X, Hinnebusch BJ, Preston JF 3rd, Romeo T. Depolymerization of beta-1, 6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. J Bacteriol 2005; 187: 382-7.
32. Römling U. Cyclic di-GMP, an established secondary messenger still speeding up. Environ Microbiol 2012; 14: 1817-29.
33. Ross P, Mayer R, Benziman M. Cellulose biosynthesis and function in bacteria. Microbiol Rev 1991; 55: 35-58.
34. Schirmer T, Jenal U. Structural and mechanistic determinants of c-di-GMP signalling. Nat Rev Microbiol 2009; 7: 724-35.
35. Tamayo R, Pratt JT, Camilli A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 2007; 61: 131-48.
36. Tran NT, Den Hengst CD, Gomez-Escribano JP, Buttner MJ. Identification and characterization of CdgB, a diguanylate cyclase involved in developmental processes in Streptomyces coelicolor. J Bacteriol 2011; 193: 3100-8.
37. Simm R, Morr M, Kader A, Nimtz M, Römling U. GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. Mol Microbiol 2004; 53: 1123-34.
38. Cotter PA, Stibitz S. c-di-GMP-mediated regulation of virulence and biofilm formation. Curr Opin Microbiol 2007; 10: 17-23.
39. Krasteva PV, Giglio KM, Sondermann H. Sensing the messenger: the diverse ways that bacteria signal through c-di-GMP. Protein Sci 2012; 21: 929-48.
40. Sondermann H, Shikuma NJ, Yildiz FH. You've come a long way: c-di-GMP signaling. Curr Opin Microbiol 2012; 15: 140-6.
41. Ryan RP, Tolker-Nielsen T, Dow JM. When the PilZ don't work: effectors for cyclic di-GMP action in bacteria. Trends Microbiol 2012; 20: 235-42.
42. Newell PD, Yoshioka S, Hvorecny KL, Monds RD, O'Toole GA. Systematic analysis of diguanylate cyclases that promote biofilm formation by Pseudomonas fluorescens Pf0-1. J Bacteriol 2011; 193: 4685-98.
43. Shikuma NJ, Fong JC, Yildiz FH. Cellular levels and binding of c-di-GMP control subcellular localization and activity of the Vibrio cholerae transcriptional regulator VpsT. PLoS Pathog 2012; 8: e1002719.
44. Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010; 5: 1663-74.
45. Meissner A, Wild V, Simm R et al. Pseudomonas aeruginosa cupA-encoded fimbriae expression is regulated by a GGDEF and EAL domain-dependent modulation of the intracellular level of cyclic diguanylate. Environ Microbiol 2007; 9: 2475-85.
46. Starkey M, Hickman JH, Ma L et al. Pseudomonas aeruginosa rugose small colony variants have adaptations likely to promote persistence in the cystic fibrosis lung. J Bacteriol 2009; 191: 3492-503.
47. Byrd MS, Pang B, Hong W et al. Direct evaluation of Pseudomonas aeruginosa biofilm mediators in a chronic infection model. Infect Immun 2011; 79: 3087-95.
48. Sun YC, Koumoutsi A, Jarrett C et al. Differential control of Yersinia pestis biofilm formation in vitro and in the flea vector by two c-di-GMP diguanylate cyclases. PLoS ONE 2011; 6: e19267.
49. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-3.
50. Lai TH, Kumagai Y, Hyodo M, Hayakawa Y, Rikihisa Y. Anaplasma phagocytophilum PleC histidine kinase and PleD diguanylate cyclase two-component system and role of cyclic di-GMP in host-cell infection. J Bacteriol 2008; 191: 693-700.
51. Kulesekara H, Lee V, Brencic A et al. Analysis of Pseudomonas aeruginosa diguanylate cyclases and phosphodiesterases reveals a role for bis-(3′-5′)-cyclic-GMP in virulence. Proc Natl Acad Sci U S A 2006; 103: 2839-44.
52. Bobrov AG, Kirillina O, Ryjenkov DA et al. Systematic analysis of cyclic di-GMP signalling enzymes and their role in biofilm formation and virulence in Yersinia pestis. Mol Microbiol 2011; 79: 533-51.
53. Petersen E, Chaudhuri P, Gourley C, Harms J, Splitter G. Brucella melitensis cyclic di-GMP phosphodiesterase BpdA controls expression of flagellar genes. J Bacteriol 2011; 193: 5683-91.
54. Tischler AD, Camilli A. Cyclic diguanylate regulates Vibrio cholerae virulence gene expression. Infect Immun 2005; 73: 5873-82.
55. Witte G, Hartung S, Buttner K, Hopfner KP. Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates. Mol Cell 2008; 30: 167-78.
56. Römling U. Great times for small molecules: c-di-AMP, a second messenger candidate in Bacteria and Archaea. Sci Signal 2008; 1: pe39.
57. Rao F, See RY, Zhang D, Toh DC, Ji Q, Liang ZX. YybT is a signaling protein that contains a cyclic dinucleotide phosphodiesterase domain and a GGDEF domain with ATPase activity. J Biol Chem 2010; 285: 473-82.
58. Chaudhuri RR, Allen AG, Owen PJ et al. Comprehensive identification of essential Staphylococcus aureus genes using Transposon-Mediated Differential Hybridisation (TMDH). BMC Genomics 2009; 10: 291.
59. Glass JI, Assad-Garcia N, Alperovich N et al. Essential genes of a minimal bacterium. Proc Natl Acad Sci U S A 2006; 103: 425-30.
60. French CT, Lao P, Loraine AE, Matthews BT, Yu H, Dybvig K. Large-scale transposon mutagenesis of Mycoplasma pulmonis. Mol Microbiol 2008; 69: 67-76.
61. Song JH, Ko KS, Lee JY et al. Identification of essential genes in Streptococcus pneumoniae by allelic replacement mutagenesis. Mol Cells 2005; 19: 365-74.
62. Rallu F, Gruss A, Ehrlich SD, Maguin E. Acid- and multistress-resistant mutants of Lactococcus lactis: identification of intracellular stress signals. Mol Microbiol 2000; 35: 517-28.
63. Thibessard A, Borges F, Fernandez A, Gintz B, Decaris B, Leblond-Bourget N. Identification of Streptococcus thermophilus CNRZ368 genes involved in defense against superoxide stress. Appl Environ Microbiol 2004; 70: 2220-9.
64. Corrigan RM, Abbott JC, Burhenne H, Kaever V, Gründling A. c-di-AMP is a new second messenger in Staphylococcus aureus with a role in controlling cell size and envelope stress. PLoS Pathog 2011; 7: e1002217.
65. M in beta-lactam resistance reveals an essential role for c-di-AMP in peptidoglycan homeostasis. Mol Microbiol 2012; 83: 623-39.
66. Woodward JJ, Iavarone AT, Portnoy DA. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010; 328: 1703-5.
67. Schwartz KT, Carleton JD, Quillin SJ, Rollins SD, Portnoy DA, Leber JH. Hyperinduction of host beta interferon by a Listeria monocytogenes strain naturally overexpressing the multidrug efflux pump MdrT. Infect Immun 2012; 80: 1537-45.
68. Bejerano-Sagie M, Oppenheimer-Shaanan Y, Berlatzky I, Rouvinski A, Meyerovich M, Ben-Yehuda S. A checkpoint protein that scans the chromosome for damage at the start of sporulation in Bacillus subtilis. Cell 2006; 125: 679-90.
69. Oppenheimer-Shaanan Y, Wexselblatt E, Katzhendler J, Yavin E, Ben-Yehuda S. c-di-AMP reports DNA integrity during sporulation in Bacillus subtilis. EMBO Rep 2011; 12: 594-601.
70. Potrykus K, Cashel M. (p)ppGpp still magical? Annu Rev Microbiol 2008; 62: 35-51.
71. Wolz C, Geiger T, Goerke C. The synthesis and function of the alarmone (p)ppGpp in firmicutes. Int J Med Microbiol 2010; 300: 142-7.
72. Battesti A, Bouveret E. Bacteria possessing two RelA/SpoT-like proteins have evolved a specific stringent response involving the acyl carrier protein-SpoT interaction. J Bacteriol 2009; 191: 616-24.
73. Atkinson GC, Tenson T, Hauryliuk V. The RelA/SpoT homolog (RSH) superfamily: distribution and functional evolution of ppGpp synthetases and hydrolases across the tree of life. PLoS ONE 2011; 6: e23479.
74. Haugen SP, Ross W, Manrique M, Gourse RL. Fine structure of the promoter-sigma region 1.2 interaction. Proc Natl Acad Sci U S A 2008; 105: 3292-7.
75. Dalebroux ZD, Swanson MS. ppGpp magic beyond RNA polymerase. Nat Rev Microbiol 2012; 10: 203-12.
76. Boehm A, Steiner S, Zaehringer F et al. Second messenger signalling governs Escherichia coli biofilm induction upon ribosomal stress. Mol Microbiol 2009; 72: 1500-16.
77. Magnusson LU, Farewell A, Nyström T. ppGpp a global regulator in Escherichia coli. Trends Microbiol 2005; 13: 236-42.
78. Traxler MF, Zacharia VM, Marquardt S et al. Discretely calibrated regulatory loops controlled by ppGpp partition gene induction across the 'feast to famine' gradient in Escherichia coli. Mol Microbiol 2011; 79: 830-45.
79. Jain V, Kumar M, Chatterji D. ppGpp stringent response and survival. J Microbiol 2006; 44: 1-10.
80. Dalebroux ZD, Svensson SL, Gaynor EC, Swanson MS. ppGpp conjures bacterial virulence. Microbiol Mol Biol Rev 2010; 74: 171-99.
81. Renier S, Hebraud M, Desvaux M. Molecular biology of surface colonization by Listeria monocytogenes: an additional facet of an opportunistic Gram-positive foodborne pathogen. Environ Microbiol 2011; 13: 835-50.
82. Lemos JA, Brown TA Jr, Burne RA. Effects of RelA on key virulence properties of planktonic and biofilm populations of Streptococcus mutans. Infect Immun 2004; 72: 1431-40.
83. Chavez de Paz LE, Lemos JA, Wickström C, Sedgley CM. Role of (p)ppGpp in biofilm formation by Enterococcus faecalis. Appl Environ Microbiol 2012; 78: 1627-30.
84. He H, Cooper JN, Mishra A, Raskin DM. Stringent response regulation of biofilm formation in Vibrio cholerae. J Bacteriol 2012; 194: 2962-72.
85. Aberg A, Shingler V, Balsalobre C. (p)ppGpp regulates type 1 fimbriation of Escherichia coli by modulating the expression of the site-specific recombinase FimB. Mol Microbiol 2006; 60: 1520-33.
86. Wu J, Long Q, Xie J. (p)ppGpp and drug resistance. J Cell Physiol 2010; 224: 300-4.
87. Pomares MF, Vincent PA, Farias RN, Salomon RA. Protective action of ppGpp in microcin J25-sensitive strains. J Bacteriol 2008; 190: 4328-34.
88. Abranches J, Martinez AR, Kajfasz JK, Chavez V, Garsin DA, Lemos JA. The molecular alarmone (p)ppGpp mediates stress responses, vancomycin tolerance, and virulence in Enterococcus faecalis. J Bacteriol 2009; 191: 2248-56.
89. Nguyen D, Joshi-Datar A, Lepine F et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 2011; 334: 982-6.
90. McDonough KA, Rodriguez A. The myriad roles of cyclic AMP in microbial pathogens: from signal to sword. Nat Rev Microbiol 2012; 10: 27-38.
91. Bai G, Knapp GS, McDonough KA. Cyclic AMP signalling in mycobacteria: redirecting the conversation with a common currency. Cell Microbiol 2011; 13: 349-58.
92. Fong JC, Yildiz FH. Interplay between cyclic AMP-cyclic AMP receptor protein and cyclic di-GMP signaling in Vibrio cholerae biofilm formation. J Bacteriol 2008; 190: 6646-59.
93. Muller CM, Aberg A, Straseviciene J, Emödy L, Uhlin BE, Balsalobre C. Type 1 fimbriae, a colonization factor of uropathogenic Escherichia coli, are controlled by the metabolic sensor CRP-cAMP. PLoS Pathog 2009; 5: e1000303.
94. Maisonneuve E, Shakespeare LJ, Jorgensen MG, Gerdes K. Bacterial persistence by RNA endonucleases. Proc Natl Acad Sci U S A 2011; 108: 13206-11.
95. Wang X, Wood TK. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. Appl Environ Microbiol 2011; 77: 5577-83.
96. Wang X, Kim Y, Hong SH et al. Antitoxin MqsA helps mediate the bacterial general stress response. Nat Chem Biol 2011; 7: 359-66.
97. Korch SB, Henderson TA, Hill TM. Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis. Mol Microbiol 2003; 50: 1199-213.
98. Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG. Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. Science 2009; 323: 396-401.
99. Van Melderen L. Saavedra De Bast M. Bacterial toxin-antitoxin systems: more than selfish entities? PLoS Genet 2009; 5: e1000437.
100. Vega NM, Allison KR, Khalil AS, Collins JJ. Signaling-mediated bacterial persister formation. Nat Chem Biol 2012; 8: 431-3.
101. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011; 473: 216-20.
102. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 2010; 8: 423-35.
103. 2S: a universal defense against antibiotics in bacteria. Science 2011; 334: 986-90.
104. Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs 2011; 34: 737-51.
105. Romero D, Traxler MF, Lopez D, Kolter R. Antibiotics as signal molecules. Chem Rev 2011; 111: 5492-505.
106. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R. D-amino acids trigger biofilm disassembly. Science 2010; 328: 627-9.
107. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 1171-5.
108. Pozzi C, Waters EM, Rudkin JK et al. Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog 2012; 8: e1002626.
109. Gallant CV, Daniels C, Leung JM et al. Common beta-lactamases inhibit bacterial biofilm formation. Mol Microbiol 2005; 58: 1012-24.
110. Purcell EB, McKee RW, McBride SM, Waters CM, Tamayo R. Cyclic diguanylate inversely regulates motility and aggregation in Clostridium difficile. J Bacteriol 2012; 194: 3307-16.
111. An S, Wu J, Zhang LH. Modulation of Pseudomonas aeruginosa biofilm dispersal by a cyclic-di-GMP phosphodiesterase with a putative hypoxia-sensing domain. Appl Environ Microbiol 2010; 76: 8160-73.
112. Roy AB, Petrova OE, Sauer K. The phosphodiesterase DipA (PA5017) is essential for Pseudomonas aeruginosa biofilm dispersion. J Bacteriol 2012; 194: 2904-15.
113. Monds RD, Newell PD, Gross RH, O'Toole GA. Phosphate-dependent modulation of c-di-GMP levels regulates Pseudomonas fluorescens Pf0-1 biofilm formation by controlling secretion of the adhesin LapA. Mol Microbiol 2007; 63: 656-79.
114. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 2011; 9: 775-85.
115. Barraud N, Storey MV, Moore ZP, Webb JS, Rice SA, Kjelleberg S. Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. Microb Biotechnol 2009; 2: 370-8.
116. Carlson HK, Vance RE, Marletta MA. H-NOX regulation of c-di-GMP metabolism and biofilm formation in Legionella pneumophila. Mol Microbiol 2010; 77: 930-42.
117. Liu N, Xu Y, Hossain S et al. Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in Shewanella woodyi. Biochemistry 2012; 51: 2087-99.
118. Morgan R, Kohn S, Hwang SH, Hassett DJ, Sauer K. BdlA, a chemotaxis regulator essential for biofilm dispersion in Pseudomonas aeruginosa. J Bacteriol 2006; 188: 7335-43.
119. Barraud N, Schleheck D, Klebensberger J et al. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol 2009; 191: 7333-42.
120. Rao F, Ji Q, Soehano I, Liang ZX. Unusual heme-binding PAS domain from YybT family proteins. J Bacteriol 2011; 193: 1543-51.
121. Delgado-Nixon VM, Gonzalez G, Gilles-Gonzalez MA. Dos, a heme-binding PAS protein from Escherichia coli, is a direct oxygen sensor. Biochemistry 2000; 39: 2685-91.
122. Barraud N, Hassett DJ, Hwang SH, Rice SA, Kjelleberg S, Webb JS. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006; 188: 7344-53.
123. Plate L, Marletta MA. Nitric oxide modulates bacterial biofilm formation through a multicomponent cyclic-di-GMP signaling network. Mol Cell 2012; 46: 449-60.
124. Ma Q, Yang Z, Pu M, Peti W, Wood TK. Engineering a novel c-di-GMP-binding protein for biofilm dispersal. Environ Microbiol 2011; 13: 631-42.
125. Ma Q, Zhang G, Wood TK. Escherichia coli BdcA controls biofilm dispersal in Pseudomonas aeruginosa and Rhizobium meliloti. BMC Res Notes 2011; 4: 447.
126. Wexselblatt E, Katzhendler J, Saleem-Batcha R et al. ppGpp analogues inhibit synthetase activity of Rel proteins from Gram-negative and Gram-positive bacteria. Bioorg Med Chem 2010; 18: 4485-97.
127. Kumagai Y, Matsuo J, Hayakawa Y, Rikihisa Y. Cyclic di-GMP signaling regulates invasion by Ehrlichia chaffeensis of human monocytes. J Bacteriol 2010; 192: 4122-33.
128. Wang J, Zhou J, Donaldson GP et al. Conservative change to the phosphate moiety of cyclic diguanylic monophosphate remarkably affects its polymorphism and ability to bind DGC, PDE, and PilZ proteins. J Am Chem Soc 2011; 133: 9320-30.
129. Nakayama S, Kelsey I, Wang J, Sintim HO. c-di-GMP can form remarkably stable G-quadruplexes at physiological conditions in the presence of some planar intercalators. Chem Commun (Camb) 2010; 47: 4766-8.
130. Kelsey I, Nakayama S, Sintim HO. Diamidinium and iminium aromatics as new aggregators of the bacterial signaling molecule, c-di-GMP. Bioorg Med Chem Lett 2012; 22: 881-5.
131. Liu C, Worthington RJ, Melander C, Wu H. A new small molecule specifically inhibits the cariogenic bacterium Streptococcus mutans in multispecies biofilms. Antimicrob Agents Chemother 2011; 55: 2679-87.
132. Rendueles O, Ghigo JM. Multi-species biofilms: how to avoid unfriendly neighbors. FEMS Microbiol Rev 2012; 36: 972-89.
133. Romero D, Aguilar C, Losick R, Kolter R. Amyloid fibers provide structural integrity to Bacillus subtilis biofilms. Proc Natl Acad Sci U S A 2011; 107: 2230-4.
134. Kolodkin-Gal I, Cao S, Chai L et al. A self-produced trigger for biofilm disassembly that targets exopolysaccharide. Cell 2012; 149: 684-92.
135. Rendueles O, Kaplan JB, Ghigo JM. Antibiofilm polysaccharides. Environ Microbiol 2012; doi: 10.1111/j.1462-2920.2012.02810.x.
136. Iwase T, Uehara Y, Shinji H et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010; 465: 346-9.
137. Karaolis DK, Rashid MH, Chythanya R, Luo W, Hyodo M, Hayakawa Y. c-di-GMP (3′-5′-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation. Antimicrob Agents Chemother 2005; 49: 1029-38.
138. Brouillette E, Hyodo M, Hayakawa Y, Karaolis DK, Malouin F. 3′, 5′-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob Agents Chemother 2005; 49: 3109-13.
139. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29: 4828-36.
140. Van Mellaert L, Shahrooei M, Hofmans D, Eldere JV. Immunoprophylaxis and immunotherapy of Staphylococcus epidermidis infections: challenges and prospects. Expert Rev Vaccines 2012; 11: 319-34.
141. Karaolis DK, Means TK, Yang D et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 2007; 178: 2171-81.
142. Sauer JD, Sotelo-Troha K, von Moltke J et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun 2011; 79: 688-94.
143. Ebensen T, Schulze K, Riese P, Morr M, Guzman CA. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol 2007; 14: 952-8.
144. Libanova R, Becker PD, Guzman CA. Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol 2012; 5: 168-76.
145. Abdul-Sater AA, Grajkowski A, Erdjument-Bromage H et al. The overlapping host responses to bacterial cyclic dinucleotides. Microbes Infect 2012; 14: 188-97.
146. McWhirter SM, Barbalat R, Monroe KM et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 2009; 206: 1899-911.
147. Burdette DL, Monroe KM, Sotelo-Troha K et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011; 478: 515-8.
148. Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzman CA. Bis-(3′, 5′)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 2011; 29: 5210-20.
149. Libanova R, Ebensen T, Schulze K et al. The member of the cyclic di-nucleotide family bis-(3′, 5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine 2010; 28: 2249-58.
150. Hu DL, Narita K, Hyodo M, Hayakawa Y, Nakane A, Karaolis DK. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 2009; 27: 4867-73.
151. Karaolis DK, Newstead MW, Zeng X et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 2007; 75: 4942-50.
152. Ogunniyi AD, Paton JC, Kirby AC et al. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine 2008; 26: 4676-85.
153. Crull K, Rohde M, Westphal K et al. Biofilm formation by Salmonella enterica serovar Typhimurium colonizing solid tumours. Cell Microbiol 2011; 13: 1223-33.
154. Christen M, Kulasekara HD, Christen B, Kulasekara BR, Hoffman LR, Miller SI. Asymmetrical distribution of the second messenger c-di-GMP upon bacterial cell division. Science 2010; 328: 1295-7.
155. Coates AR, Hu Y. Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci 2008; 29: 143-50.
156. Steinberger O, Lapidot Z, Ben-Ishai Z, Amikam D. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3′, 5′-cyclic diguanylic acid. FEBS Lett 1999; 444: 125-9.
157. Karaolis DK, Cheng K, Lipsky M et al. 3′, 5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun 2005; 329: 40-5.
158. Wang X, Lünsdorf H, Ehren I, Brauner A, Römling U. Characteristics of biofilms from urinary tract catheters and presence of biofilm-related components in Escherichia coli. Curr Microbiol 2010; 60: 446-53.
159. Wu H, Song Z, Hentzer M et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother 2004; 53: 1054-61.
160. Jakobsen TH, van Gennip M, Phipps RK et al. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob Agents Chemother 2012; 56: 2314-25.
161. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34: 349-57.
162. Alemayehu D, Casey PG, McAuliffe O et al. Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. mBio 2012; 3: e00029-12.
163. Smyth AR, Cifelli PM, Ortori CA et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial. Pediatr Pulmonol 2010; 45: 356-62.